Skip to main content
. 2012 May 29;33(17):2197–2205. doi: 10.1093/eurheartj/ehs136

Figure 3.

Figure 3

Combination of mid-regional pro-atrial natriuretic peptide and mid-regional pro-adrenomedullin for multimarker risk assessment in dyspnoea. Patients with mid-regional pro-atrial natriuretic peptide >194 pmol/L and mid-regional pro-adrenomedullin >0.77 nmol/L had the highest risk.